Community pharmacists are well-placed to report adverse drug reactions (ADRs) via yellow cards but often fall behind hospital colleagues in the number of reports submitted. One reason may be not knowing what to report.

MHRA guidelines

MHRA guidelines on what should be reported include:
• Serious reactions
• Anything that involves a medicine on additional monitoring
• An unlisted reaction in product information
• Anything you are unsure about reporting.

It is often asked ‘what constitutes a serious reaction’? An ADR which was fatal or life-threatening would be obviously classified as serious. However, there are other categories of serious reaction: these might include an ADR that results in hospitalisation or a prolonged hospital stay; one that results in disablement; or those causing congenital abnormalities.

Medically significant ADRs are also classified as serious reactions. These are those that do not meet the other criteria but where the ADR might result in harm to the patient and might require treatment.

Causality does not need to be established when submitting a yellow card. The MHRA’s guidance is, if in doubt – report it. So how can community pharmacists increase reporting?

The conversations community pharmacists have with their patients make them ideally placed to identify any ADRs:
• MUR and NMS consultations are specifically designed to highlight any issues a patient might be having with their medicine, including ADRs, leading to a yellow card report
• As suppliers of herbal and OTC medicines, pharmacists can identify any issues when talking to patients about these drugs
• Patients may not be aware that they can report ADRs. By talking to patients, running yellow card awareness events, and having the reporting telephone number and website address on hand, reporting may be increased.

Useful sources

Increasing your knowledge about ADRs and yellow cards and that of your team will also help. Useful sources of further information include:
• CPPE’s e-learning course for pharmacy professionals on ADRs, yellow cards and pharmacovigilance:
• MHRA guidance on the yellow card scheme for healthcare professionals:
• Signing up for monthly updates at
• The yellow card mobile phone app, which allows a watch list to be created to receive medication alerts and yellow cards to be submitted.

The MHRA guidance is – if in doubt, report it


CPPE: Do you have the right skill mix in your pharmacy?

CPPE’s updated ‘Skill mix’ e-learning programme will help pharmacists conduct an effective skill mix review

UKCPA viewpoint: Miconazole and warfarin

Warnings about miconazole oral gel and warfarin prescribed together are still not being heeded putting patients risk


Health checks and diabetes prevention New Style

This module provides an update on both the NHS Health Check and NHS diabetes prevention programmes

CPD: Anxiety disorders in adults New Style

This module will help you understand the main types of anxiety disorder and their therapeutic management

Dovonex is switched from POM to P

Dovonex Psoriasis Ointment (calcipotriol 50mcg/g) has been reclassified as a P medicine, the MHRA has announced